Alcoholism

— First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company Reiterates 2025 Financial Expectations — DUBLIN , May 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain focused on executing on the strategic objectives that we believe will drive the future value of the company," said Richard Pops , Chief Executive Officer of Alkermes. "We recently achieved an important milestone in the program for ALKS 2680, our novel, investigational, oral orexin 2 receptor agonist, completing enrollment in our first phase 2 study in the program, Vibrance-1, in narcolepsy type 1. We now expect topline results from Vibrance-1 early in the third quarter. We expect to complete enrollment in the Vibrance-2 phase 2 study, in narcolepsy type 2, mid-year, with topline data from that study expected in the fall. Enrollment in Vibrance-3, our phase 2 study in idiopathic hypersomnia, is now also underway. Across the ALKS 2680 development program, we have strong momentum and are preparing for the phase 3 program. With the potential to transform the treatment of central disorders of hypersomnolence, orexin 2 receptor agonists are one of the most exciting new therapeutic categories in development." Key Financial Highlights Revenues (In millions) Three Months Ended March 31 , 2025 2024 Total Revenues $ 306.5 $ 350.4 Total Proprietary Net Sales $ 244.5 $ 233.5 VIVITROL® $ 101.0 $ 97.7 ARISTADA®i $ 73.5 $ 78.9 LYBALVI® $ 70.0 $ 57.0 Profitability (In millions) Three Months Ended March 31 , 2025 2024 GAAP Net Income From Continuing Operations $ 22.5 $ 38.9 GAAP Net Income (Loss) From Discontinued Operations $ -- $ (2.1) GAAP Net Income $ 22.5 $ 36.8 EBITDA From Continuing Operations $ 22.8 $ 51.5 EBITDA From Discontinued Operations $ -- $ (2.5) EBITDA $ 22.8 $ 49.0 Adjusted EBITDA $ 45.6 $ 81.8 Revenue Highlights LYBALVI Revenues for the quarter were $70.0 million . Revenues and total prescriptions for the quarter grew 23% and 22%, respectively, compared to the first quarter of 2024. ARISTADAi Revenues for the quarter were $73.5 million . VIVITROL Revenues for the quarter were $101.0 million . Manufacturing & Royalty Revenues VUMERITY® manufacturing and royalty revenues for the quarter were $27.8 million . Royalty revenues from XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® for the quarter were $17.7 million . Key Operating Expenses Please see Note 1 below for details regarding discontinued operations. (In millions) Three Months Ended March 31 , 2025 2024 R&D Expense – Continuing Operations $ 71.8 $ 67.6 R&D Expense – Discontinued Operations $ -- $ 2.5 SG&A Expense – Continuing Operations $ 171.7 $ 179.7 SG&A Expense – Discontinued Operations $ -- $ -- Balance Sheet At March 31, 2025 , the company recorded cash, cash equivalents and total investments of $916.2 million , compared to $824.8 million at Dec. 31, 2024. Financial Expectations for 2025Alkermes reiterates its financial expectations for 2025, as set forth in its press release dated Feb. 12, 2025 . Notes and Explanations1. The company determined that upon the separation of its former oncology business, completed on Nov. 15, 2023 , the oncology business met the criteria for discontinued operations in accordance with Financial Accounting Standards Board Accounting Standards Codification 205, Discontinued Operations. Accordingly, the accompanying selected financial information has been updated to present the results of the oncology business as discontinued operations for the three months ended March 31, 2024 . Conference CallAlkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET ( 1:00 p.m. BST ) on Thursday, May 1, 2025 , to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland , Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio . For more information, please visit Alkermes' website at www.alkermes.com. Non-GAAP Financial MeasuresThis press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share-based compensation expense in addition to the components of EBITDA from earnings. The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP financial measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, EBITDA and Adjusted EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, EBITDA and Adjusted EBITDA should not be considered measures of the company's liquidity. A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. Note Regarding Forward-Looking StatementsCertain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning its future financial and operating performance, business plans or prospects, including expected value drivers; and the company's expectations regarding development plans, activities and timelines for, and the potential therapeutic and commercial value of, ALKS 2680. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether the company is able to achieve its financial expectations; clinical development activities may not be completed on time or at all; the results of the company's development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the U.S. Food and Drug Administration (FDA) or regulatory authorities outside the U.S. may not agree with the company's regulatory approval strategies or may make adverse decisions regarding the company's products; the unfavorable outcome of arbitration, litigation, or other proceedings or disputes related to the company's products or products using the company's proprietary technologies; the company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release. VIVITROL® is a registered trademark of Alkermes, Inc. ; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited , used by Alkermes, Inc. under license; BYANNLI®, INVEGA HAFYERA®, INVEGA TRINZA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson or its affiliated companies; and VUMERITY® is a registered trademark of Biogen MA Inc. , used by Alkermes under license. ________________________________ i The term "ARISTADA" as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise. Alkermes plc and Subsidiaries Selected Financial Information (Unaudited) Condensed Consolidated Statements of Operations - GAAP Three Months Ended Three Months Ended (In thousands, except per share data) March 31, 2025 March 31, 2024 Revenues: Product sales, net $ 244,493 $ 233,536 Manufacturing and royalty revenues 62,017 116,833 Research and development revenue — 3 Total Revenues 306,510 350,372 Expenses: Cost of goods manufactured and sold 49,197 58,644 Research and development 71,817 67,611 Selling, general and administrative 171,704 179,749 Amortization of acquired intangible assets — 1,059 Total Expenses 292,718 307,063 Operating Income 13,792 43,309 Other Income, net: Interest income 10,141 9,399 Interest expense — (5,978) Other income, net 1,556 182 Total Other Income, net 11,697 3,603 Income Before Income Taxes 25,489 46,912 Income Tax Provision 3,025 7,964 Net Income From Continuing Operations 22,464 38,948 Loss from Discontinued Operations — Net of Tax — (2,120) Net Income — GAAP $ 22,464 $ 36,828 GAAP Earnings (Loss) Per Share - Basic: From continuing operations $ 0.14 $ 0.23 From discontinued operations — (0.01) Earnings per share $ 0.14 $ 0.22 GAAP Earnings (Loss) Per Share - Diluted: From continuing operations $ 0.13 $ 0.23 From discontinued operations — (0.01) Earnings per share $ 0.13 $ 0.21 Weighted Average Number of Ordinary Shares Outstanding: Basic — GAAP 163,407 167,984 Diluted — GAAP 168,737 172,981 Condensed Consolidated Statements of Operations - GAAP (Continued) Three Months Ended Three Months Ended (In thousands, except per share data) March 31, 2025 March 31, 2024 An itemized reconciliation between net income from continuing operations on a GAAP basis and Adjusted EBITDA is as follows: Net Income from Continuing Operations $ 22,464 $ 38,948 Adjustments: Depreciation and amortization expense 7,421 8,056 Interest income (10,141) (9,399) Interest expense — 5,978 Income tax provision 3,025 7,964 EBITDA from Continuing Operations 22,769 51,547 EBITDA from Discontinued Operations — (2,516) EBITDA 22,769 49,031 Share-based compensation 22,810 32,755 Adjusted EBITDA $ 45,579 $ 81,786 Alkermes plc and Subsidiaries Selected Financial Information (Unaudited) Condensed Consolidated Balance Sheets March 31 , December 31 , (In thousands) 2025 2024 Cash, cash equivalents and total investments $ 916,206 $ 824,816 Receivables 318,703 389,733 Inventory 183,438 182,887 Contract assets 3,049 4,990 Prepaid expenses and other current assets 89,843 86,077 Property, plant and equipment, net 233,920 227,564 Intangible assets, net and goodwill 83,899 83,917 Deferred tax assets 152,144 154,835 Other assets 100,775 100,748 Total Assets $ 2,081,977 $ 2,055,567 Accrued sales discounts, allowances and reserves $ 249,795 $ 272,452 Other current liabilities 193,935 192,747 Other long-term liabilities 126,664 125,391 Total shareholders' equity 1,511,583 1,464,977 Total Liabilities and Shareholders' Equity $ 2,081,977 $ 2,055,567 Ordinary shares outstanding (in thousands) 164,853 162,177 This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 , which the company intends to file in May 2025 . Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-plc-reports-first-quarter-2025-financial-results-302443339.html SOURCE Alkermes plc

– Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking – – Respondents Cited the Influence of Their Healthcare Providers and the Positive Impact of Treatment on Their Lives – DUBLIN, April 30, 2025 /PRNewswire/ -- A new online survey conducted by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), sought to understand utilization of and experiences with treatment among 300 adults between ages 21-64 who self-identify as having been diagnosed with alcohol use disorder (AUD) by a healthcare provider. The survey showed that the path to AUD diagnosis can be challenging and often driven by negative consequences, but treatment may positively impact people living with AUD. The survey is part of Alkermes' ongoing commitment to understanding the unique needs of people who are living with a substance use disorder and supporting increased disease state awareness and education. This data builds on research Alkermes previously conducted with The Harris Poll exploring patterns related to heavy drinking and diagnosis. Continue Reading View PDF Living with Alcohol Use Disorder (AUD): Adults with AUD share insights into their diagnosis and treatment journeys AUD is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational or health consequences. A person living with AUD often needs to drink greater amounts of alcohol to experience its effect and experiences withdrawal symptoms after stopping alcohol use. AUD can affect physical and mental health, and can cause problems with family, friends and work.1 According to the U.S. 2023 National Survey on Drug Use and Health, approximately 28 million adults ages 18 and older had AUD in the past year,2 but only about 2 million received treatment—which could include inpatient or outpatient care, prescription medication and/or professional counseling—for alcohol use in the past year.3 "Despite increased awareness of AUD, many individuals living with this condition still struggle with stigma and feelings of shame, which can make it challenging to seek help. It's important to understand that AUD is a medical condition—both diagnosable and treatable—with a range of effective treatment options, including medical and psychosocial supports," said Sarah Church, Ph.D., Clinical Psychologist and Founder and Executive Director of Wholeview in New York, NY. "This survey demonstrates that engaging in treatment can lead to meaningful, positive outcomes and highlights the critical role that healthcare providers play in supporting patients throughout their recovery journey. These findings should motivate all of us to prioritize proactive screening so that individuals can be identified early and connected with medical care and support." Key findings from the survey include: The path to AUD diagnosis is influenced by a number of factors and often prompted by negative mental, physical and psychosocial impacts. 47% of respondents were diagnosed as the result of a hospital or emergency room (ER) visit because they were experiencing AUD symptoms or were involved in an alcohol-related incident, such as driving under the influence (DUI) or a car accident. For approximately one-third of respondents, diagnosis was driven by factors including: personal concern about alcohol use and desire to discuss with their healthcare provider (36%); a visit with a healthcare provider about symptoms that ended up being related to their AUD (35%); and concerns or encouragement from a loved one to see a healthcare provider (32%). A majority (79%) of those surveyed responded that they had negative feelings when initially diagnosed, including feeling scared (38%), ashamed (33%), concerned (32%) and embarrassed (32%). Motivations for seeking treatment and types of treatment people engage in vary over the course of a recovery journey, reflecting the individuality of experience and importance of treatment and support options. 83% of those surveyed agreedi with the statement that "it's difficult to treat/manage AUD through willpower alone". Among those who had ever been treated for AUD, their motivation for seeking treatment included: negative impact of AUD on physical health (39%); negative impact of AUD on mental health (38%); advice from a healthcare provider (36%); advice/encouragement from family/friends (33%); and negative impact of AUD on day-to-day life (31%). Among those surveyed, many had engaged in treatment: 70% reported currently being treated for AUD; 28% reported they have been treated in the past, but are no longer being treated; and 2% indicated that they have never been treated for AUD. Among those who had ever been treated, respondents cited current use of a wide variety of treatment types: 50% were taking prescription medication; 46% were participating in behavioral therapy; 43% were involved in support group therapy; 43% were using alternative treatments; 42% were undergoing detox treatment; 38% were engaged in outpatient rehabilitation; and 32% were engaged in inpatient rehabilitation. Healthcare providers play a critical role in diagnosis and helping patients navigate the treatment landscape; however, rates of diagnosis from routine screenings remain low. In terms of which healthcare provider diagnosed them, 33% of respondents indicated that they were diagnosed by an addiction specialist and 26% by a primary care physician. 80% of all respondents indicated that they had discussed the use of prescription medication to treat their AUD with a healthcare provider and, among those who currently use prescription medication to treat their AUD, 50% chose their current medication treatment because their healthcare provider recommended it. Only 28% of respondents indicated that they were diagnosed as the result of a screening during a standard healthcare visit. Treatment has a positive impact on respondents' lives and those currently in treatment report motivation to continue on their path. Among those who had ever been treated for AUD, over half responded that AUD treatment has had a positiveii impact across various aspects of their life, including physical health (61%), overall quality of life (60%), relationships with [their] children (60%iii), work/career or ability to work (59%iv), mental health (59%), hobbies/interests (58%), relationship with friends (57%), relationship with spouse/partner (57%), finances (57%), romantic life (57%), and social life (55%). Among those currently being treated for AUD, 96% were satisfiedv with their current treatment and 96% were motivatedvi to adhere to their current treatment. "According to 2023 data from the National Institute on Alcohol Abuse and Alcoholism, more than 28 million adults in the U.S. had alcohol use disorder in the past year, underscoring an ongoing crisis in this country. Despite the high prevalence of AUD, treatment rates and awareness of treatment options remain low," said Kanchan Relwani, M.D., Senior Vice President, Medical Affairs at Alkermes. "As a company with a history of leadership in the treatment of substance use disorders, we remain committed to understanding the complex experiences of people living with AUD, including barriers and opportunities along their diagnosis and treatment journey. Our hope is that these insights will deepen our collective understanding of AUD and raise awareness of the barriers keeping people from the care they may need." i All "agree" percentages represent a sum of the proportion of respondents who selected "somewhat agree" and those who selected "strongly agree" in response to the question asked. ii All "positive" percentages represent a sum of the proportion of respondents who selected "very positive" and those who selected "somewhat positive" in response to the question asked. iii Among parents (i.e., adults who are the parent or legal guardian of a child(ren) of any age) iv Among employed adults (i.e., adults who are full-time, part-time, or self- employed) v All "satisfied" percentages represent a sum of the proportion of respondents who selected "very satisfied" and those who selected "somewhat satisfied" in response to the question asked. vi All "motivated" percentages represent a sum of the proportion of respondents who selected "very motivated" and those who selected "somewhat motivated" in response to the question asked. Survey Methodology The survey was conducted online in the United States by The Harris Poll on behalf of Alkermes, Inc. from August 15 – 27, 2024 among 300 adults between the ages of 21-64 who had been diagnosed with alcohol use disorder (AUD) or alcohol dependence. Raw data were not weighted and are therefore only representative of the individuals who completed the survey. Respondents for this survey were selected from among those who have agreed to participate in Harris Poll surveys. The sampling precision of Harris online polls is measured by using a Bayesian credible interval. For this study, the sample data is accurate to within ± 5.6 percentage points using a 95% confidence level. This credible interval will be wider among subsets of the surveyed population of interest. All sample surveys and polls, whether or not they use probability sampling, are subject to other multiple sources of error which are most often not possible to quantify or estimate, including but not limited to coverage error, error associated with nonresponse, error associated with question wording and response options, and post-survey weighting and adjustments. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact [email protected]. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at . About The Harris Poll The Harris Poll is a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. It works with clients in three primary areas: building twenty-first-century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. One of the longest running surveys in the U.S., The Harris Poll has tracked public opinion, motivations and social sentiment since 1963, and is now part of Stagwell, the challenger holding company built to transform marketing. References: 1 National Institute on Alcohol Abuse and Alcoholism (NIAAA). Alcohol's Effects on Health: Understanding Alcohol Use Disorder. Updated September 2024. Accessed April 2025. 2 National Institute on Alcohol Abuse and Alcoholism (NIAAA). Alcohol's Effects on Health: Alcohol Use Disorder (AUD) in the United States: Age Groups and Demographic Characteristics. Updated 2024. Accessed April 2025. 3 National Institute on Alcohol Abuse and Alcoholism (NIAAA). Alcohol's Effects on Health: Alcohol Treatment in the United States. Updated 2024. Accessed April 2025. Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Marisa Borgasano, +1 781 609 6659 SOURCE Alkermes plc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Ingelheim, Germany, Oxford and Belfast, UK, April 29, 2025 – Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining forces to provide insights into the day-to-day experiences of people living with psychiatric disorders, and how these experiences relate to their brain activity. The first-of-its-kind study will use novel technology to quantify brain activity, mood, and behavior at home in people who have been diagnosed with borderline personality disorder (BPD), an often neglected group of patients. The aims are to explore the acceptability of this technology in patients and gain quantitative, fine-grained, insights that could potentially guide the research and development of much-needed new therapies. Current clinical and lab-based assessments rely on retrospective recall of symptoms. They are thus limited by how accurately patients remember past events and only provide a snapshot in time of an individual’s clinical state. Moreover, self-reported questionnaires lack objectivity. This can lead to an incomplete or inaccurate picture of the overall experience of the individual and the failure of new medicines in clinical studies. This new study aims to change that. It will use Cumulus´ NeuLogiq® neuroassessment platform for the first time in people diagnosed with borderline personality disorder. This platform enables the tracking of brain function over time, both in the clinic, and from the comfort of a study participant’s home. Participants use a tablet to perform gamified versions of established objective behavioral tasks, while wearing the NeuLogiq headset which records EEG (electroencephalogram) brain waves that are precisely time-synced to the tasks. The intent is to capture data that will provide a more accurate picture of brain network activity.  In 2019, one in eight people worldwide were estimated to be living with a mental health condition, and half of the adult population can expect to experience a mental illness by age 75.i,ii*  People diagnosed with severe mental health conditions experience reduced life expectancy relative to the general population, with around 14 years of potential life lost,1 and the economic consequences of mental health conditions can be enormous.iii That’s why Boehringer Ingelheim is embracing ‘Precision Psychiatry’. This in-depth research approach delves into the neurobiology of symptoms with the goal of uncovering more targeted and holistic treatment solutions that address specific symptoms in people living serious mental illness to help them to live fulfilling lives. Kate Saunders, Associate Professor in the Department of Psychiatry of the University of Oxford says, “People diagnosed with borderline personality disorder experience a range of symptoms, including changeable mood, impulsivity, and associated difficulties in interpersonal relationships, all of which can have a significant impact on their lives. We're looking forward to exploring this new technology in people living with BPD, in collaboration with the scientists at Cumulus and Boehringer Ingelheim, to gain new insights into the mechanisms which underpin the symptoms people given this diagnosis experience.  This could open up pathways for the development of new therapies.” Dr. Hugh Marston, Senior Vice President and Global Head Neuroscience & Mental Health, Boehringer Ingelheim says, “Boehringer Ingelheim is committed to developing novel therapeutics to address the major unmet needs of people living with mental health disorders. If this platform is successfully validated in this patient population, it could be a game-changer for studies investigating novel precision psychiatry treatments. It could help us identify biomarkers for stratification and provide a rich dataset for reverse-translation.” “Many psychiatric conditions disrupt cognitive function, meaning that patients may find it harder to manage their daily life or continue to work effectively,” said Brian Murphy, PhD, Co-founder and Chief Scientific Officer of Cumulus. “These underappreciated symptoms can change from day to day, so frequent real-world measurement is important if we want to find new therapies that improve activities of daily living and quality of life. Today, we are fortunate that wearable technologies and AI are enabling a new era of drug development where we can understand objectively how a drug affects cognitive function and the underlying brain mechanisms that drive it.”  The study will be conducted by the Department of Psychiatry of the University of Oxford at the Warneford Hospital. It will frequently collect EEG and behavioral assessments, alongside remote measures of mood and activity. The main aims are to assess the feasibility of using the Cumulus platform in young adults aged 18-35 and to provide a rich dataset about brain activity and behavior in BPD for in-depth analysis.  Thirty participants who have been diagnosed with BPD and 20 participants with no diagnosed mental health disorder will be recruited. Dr. Lauren Atkinson, from the Department of Psychiatry who will be senior researcher on the study says, “We are looking forward to working with people diagnosed with borderline personality disorder and prioritising research important to them. One of the key features of a BPD diagnosis is affective dysregulation. By regularly capturing mood, alongside measures of brain activity and cognitive function over an extended period of time, we hope to better capture patient experience and use objective measures to understand more about what is happening at those key moments.” *The mental health conditions studied in this epidemiological research included: panic disorder and/or agoraphobia, generalized anxiety disorder, post-traumatic stress disorder, social phobia, specific phobia, major depressive disorder, bipolar disorder, alcohol abuse disorder, alcohol dependence disorder, drug abuse disorder, drug dependence disorder, attention deficit/hyperactivity disorder, and intermittent explosive disorder.About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com (global) or www.boehringer-ingelheim.com/uk (UK). About Cumulus Neuroscience Our mission is to generate the data and insights required to accelerate the diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world. At Cumulus Neuroscience we are advancing NeuLogiq®, an AI-based, multi-domain digital biomarker platform designed with 10 of the world's leading pharma companies. This novel platform provides the critical data and insights needed for faster, more robust and cost-effective decision-making in clinical trials and patient care. NeuLogiq enables study sponsors to capture large amounts of real-world clinical data repeatedly over time, across multiple behavioral and physiological domains, in the clinic and at home. Together with machine learning (ML) analytics, Cumulus simplifies and improves the robustness of CNS clinical trials, providing objective assessment of study inclusion and treatment outcomes. About Oxford University The University Department of Psychiatry’s mission is to conduct world-class research, teach psychiatry to medical students, develop future researchers in a graduate programme, teach doctors in training, promote excellence in clinical practice, and develop and provide innovative clinical services. It supports research in four key areas: neurobiology, psychological treatments, developmental psychiatry and social psychiatry. The Department is committed to the translation of scientific discovery into benefits for patients. www.psych.ox.ac.uk  Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the ninth year running, and ​number 3 in the QS World Rankings 2024. At the heart of this success are the twin-pillars of our ground-breaking research and innovation and our distinctive educational offer. Oxford is world-famous for research and teaching excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research alongside our personalised approach to teaching sparks imaginative and inventive insights and solutions. Through its research commercialisation arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 300 new companies since 1988. Over a third of these companies have been created in the past five years. The university is a catalyst for prosperity in Oxfordshire and the United Kingdom, contributing £15.7 billion to the UK economy in 2018/19, and supports more than 28,000 full time jobs. Media Contacts  Boehringer Ingelheim: Dr. Reinhard Malin Boehringer Ingelheim Corporate Center GmbH  Innovation Unit/Bio Comms, Corp. Affairs  Media + PR  press@boehringer-ingelheim.com  Cumulus:Tina Sampath tina.sampath@cumulusneuro.com Oxford University: Lisa Jones Communications Manager Department of Psychiatry, University of Oxford, Warneford Hospital lisa.jones@psych.ox.ac.uk